Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript
Thanks, operator. Thank you for joining us for Exact Sciences' third-quarter 2024 conference call. On the call today are ...
Exact Sciences Poised for Recovery and Long-Term Growth Amidst Challenges
Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...
Madison-based Exact Sciences reports Q3 results short of analysts’ expectations
The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.
Investopedia6d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential. Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer ...
Benzinga.com7d
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates
“The Exact Sciences’ team is helping eradicate cancer while strengthening our platform and growing our business efficiently,” said Kevin Conroy, CEO of Exact Sciences. “During the third quarter, we ...
Seeking Alpha7d
Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript
You may begin. Thanks, Operator. Thank you for joining us for Exact Sciences third quarter 2024 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO; and Aaron ...
Exact Sciences Stock Falls After Cutting Outlook, Posting Lower-Than-Expected 3Q Results
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.